In individuals with CPI-naive metastatic melanoma, the objective response rates were comparable to PD1 blocking alone, as PD1 blockade works through the expansion of pre-existing antigen-specific T cells, many of which target mutation-derived neoantigens. The gene discussed is PDCD1; the disease is metastatic melanoma.